Pathogenesis of Long COVID

Assessment of Needs

Rapid advances in knowledge about the biologic mechanisms that cause COVID-19 and its symptoms require the ongoing attention of practitioners involved in direct patient care. This webinar will address the implications of new information on the pathogenesis of long COVID, including current and ongoing research and gaps in knowledge.

Learning Objectives

On completion of this activity, learners will be able to:

• Describe the important and persistent damage on numerous body organs and tissues associated with long COVID
• Detail the current understanding of the pathogenesis of the long COVID syndrome
• List current knowledge gaps and research priorities in long COVID pathogenesis

Registration

Who Should Attend

This webinar is designed for clinical decision-makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, January 16, 2024, 10:30 AM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Paredes reported serving on advisory boards for Gilead Sciences, Inc, Pfizer, Inc, Roche Therapeutics, MSD, GSK, ViiV Healthcare, Eli Lilly and Company, and Atea Pharmaceuticals, Inc.; he reported research grants paid to his institution from MSD, ViiV Healthcare, Gilead Sciences, and PharmaMar. (Updated June 8, 2023)

Moderator

Dr Peluso reported consulting income from AstraZeneca and Gilead Sciences, Inc. (Updated March 29, 2023)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/